Account
Articles
15.07.2015
The future of the Cancer Drug Fund

NHS England have recently proposed that NICE should take a more direct role in determining which pro...

Read more
Articles
28.02.2015
New frontiers for Avastin

New legislation has enabled AIFA to approve reimbursement for Avastin for off-label usage in the tre...

Read more
News
27.02.2015
Includes Biosimilar discounts, recent developments

This issue includes topics such as the recent AIFA approval of Avastin for off label use in Wet-AMD ...

Read more
News
19.02.2015
Should the UK have a cost per QALY threshold

Should the UK have a cost per QALY threshold

Read more
Newer

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch